“Guggenheim Reduces Trade Desk Price Target to $55, Retains Buy Rating”
Guggenheim revises its price target for digital advertising titan, The Trade Desk, amidst market uncertainty and rising competition, notably from Amazon. Despite reducing the price target, Guggenheim maintains its Buy rating, highlighting the company's growth potential driven by the adoption of connected TV, political advertising, and audio monetization. Read more
Read More“MoonLake Immunotherapeutics Struggles with Downgrade Following Trial Results”
MoonLake Immunotherapeutics, a key figure in the biopharmaceutical industry, faces a turbulent market due to intense competition and the recent downgrading of its stock from "Buy" to "Hold" by Jefferies. With sonelokimab's trial outcomes impacting the company's value significantly, it underlines the critical role of successful clinical trials in investor confidence and market value. Read more
Read More
“American Rebel Holdings Initiates Reverse Stock Split”
American Rebel Holdings (NASDAQ:AREB) announces a reverse stock split to boost share price, slated for October 3, 2025. Consolidating 20 shares into 1, the company seeks to enhance marketability and appeal to investors amid market fluctuations. It remains in compliance with Nasdaq's bid price rule. Read more
Read More